Clinical Trial of the PfSPZ Vaccine
A Phase 1/2a Trial of the PfSPZ Vaccine Administered Subcutaneously or Intradermally to Malaria-Naïve Adult Volunteers
8 other identifiers
interventional
80
1 country
2
Brief Summary
The purpose of this study is to determine the safety and tolerability of a non-replicating, metabolically active Plasmodium falciparum sporozoite (PfSPZ) vaccine in malaria-naïve healthy volunteers following multiple-dose subcutaneous (SC) or intradermal (ID) administration. In addition, the investigators wish to evaluate PfSPZ vaccine-mediated protection against P. falciparum challenge in the following 4 groups (see below) and compare protective efficacy of the PfSPZ vaccine when given by SC v ID administration in all these groups:
- Group 1: 4 doses of 7,500 PfSPZ/immunization,
- Group 2: 4 doses of 30,000 PfSPZ/immunization,
- Group 3: 4 doses of 135,000 PfSPZ/immunization
- Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization. If \> 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Apr 2009
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2009
CompletedFirst Submitted
Initial submission to the registry
October 22, 2009
CompletedFirst Posted
Study publicly available on registry
October 26, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2010
CompletedSeptember 10, 2014
September 1, 2014
1.2 years
October 22, 2009
September 9, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To determine the safety and tolerability of a non-replicating, metabolically active Plasmodium falciparum sporozoite (PfSPZ) vaccine in malaria-naïve healthy volunteers following multiple-dose subcutaneous (SC) or intradermal (ID) administration.
October 2010
Secondary Outcomes (2)
To evaluate PfSPZ vaccine-mediated protection against P. falciparum challenge in the 4 groups.
October 2010
To compare protective efficacy of the PfSPZ vaccine when given by SC versus ID administration in all groups.
October 2010
Study Arms (4)
Group 1
EXPERIMENTAL4 doses of 7,500 PfSPZ/immunization.
Group 2
EXPERIMENTAL4 doses of 30,000 PfSPZ/immunization
Group 3
EXPERIMENTAL4 doses of 135,000 PfSPZ/immunization
Group 4
EXPERIMENTAL4 or 6 doses of 135,000 PfSPZ/immunization.
Interventions
Group 1: 4 doses of 7,500 PfSPZ/immunization, Group 2: 4 doses of 30,000 PfSPZ/immunization, Group 3: 4 doses of 135,000 PfSPZ/immunization, and Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization. If \> 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose.
Eligibility Criteria
You may qualify if:
- Healthy adults (male or non-pregnant female) 18-50 years of age, inclusive.
- Able and willing to participate for the duration of the study.
- Able and willing to provide written (not proxy) informed consent.
- Women of childbearing potential must agree to use effective means of birth control through the duration of the study.
- Willing to refrain from blood donation (except as required in this study) for 3 years following P. falciparum challenge.
- Agree not to travel to a malaria endemic region during the entire course of the trial.
You may not qualify if:
- Any history of malaria infection, or travel to a malaria endemic region within 6 months prior to first immunization.
- History of long term residence (\>5 years) in area known to have significant transmission of P. falciparum.
- Positive HIV, HBsAg or HCV serology. Positive sickle cell screening test.
- Has evidence of increased cardiovascular disease risk (defined as \> 10%, 5 year risk) as determined by the method of Gaziano (Gaziano 2008). Risk factors include sex, age (years), systolic blood pressure (mm Hg), smoking status, body mass index (BMI, kg/mm2), reported diabetes status, and blood pressure.
- Current use of systemic immunosuppressant pharmacotherapy.
- An abnormal EKG, defined as one showing pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm excluding isolated premature atrial contractions; right or left bundle branch block; or advanced (secondary or tertiary) A-V heart block.
- Current significant medical condition (cardiovascular, hepatic, renal, or hematological) or evidence of any other serious underlying medical condition identified by medical history, physical examination, or laboratory examination.
- History of a splenectomy.
- History of any other illness or condition which, in the investigator's judgment, may substantially increase the risk associated with the volunteer's participation in the protocol or compromise the scientific objectives. This may include psychiatric disorders (such as personality disorders, anxiety disorders, or schizophrenia) or behavioral tendencies (including active alcohol or drug abuse) discovered during the screening process that in the opinion of the investigator would make compliance with the protocol difficult.
- Plan for surgery between enrollment and challenge.
- Females who are pregnant or nursing, females who plan on becoming pregnant or plan to nurse during the study period.
- Known allergy to any component of the vaccine formulation, history of anaphylactic response to mosquito bites, retinal or visual field changes, or known allergy to the anti-malarial chloroquine phosphate, which will be used to treat volunteers developing malaria after P. falciparum challenge.
- Participation in any study involving another investigational vaccine or drug within 90 days prior to the screening visit, or plan to participate in another investigational vaccine/drug research during or within 1 month following participation in this study.
- Personal beliefs that prohibit the receiving of vaccine product containing human serum albumin within the diluent.
- Use or planned use of any drug with anti-malarial activity that would coincide with immunization or challenge.
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sanaria Inc.lead
- The PATH Malaria Vaccine Initiative (MVI)collaborator
Study Sites (2)
The Center for Vaccine Development, University of Maryland (CVD/UMB)
Baltimore, Maryland, 21201, United States
Naval Medical Research Center (NMRC) Clinical Trials Center, on the campus of the National Naval Medical Center (NNMC)
Bethesda, Maryland, 20889-5607, United States
Related Publications (1)
Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Richie TL, Seder RA, Hoffman SL. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science. 2011 Oct 28;334(6055):475-80. doi: 10.1126/science.1211548. Epub 2011 Sep 8.
PMID: 21903775RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Judith E Epstein, M.D.
Naval Medical Research Center
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 22, 2009
First Posted
October 26, 2009
Study Start
April 1, 2009
Primary Completion
July 1, 2010
Study Completion
September 1, 2010
Last Updated
September 10, 2014
Record last verified: 2014-09